Integrating is at our epicenter, bringing together leading-edge expertise with a proven track record to achieve unprecedented immunology medicines
Seismic Therapeutic™ is making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. We have brought together a stellar team of leading immunology drug developers, machine learning innovators and company builders who are charting new drug discovery territory to open better and faster ways to make medicines for patients with autoimmune and other immunological diseases. Guided by an experienced board of directors and world renowned scientific founders, Seismic is a product-centric, patient-focused immunology company with a growing biologics pipeline to control dysregulated adaptive immunity, derived from our machine-learning IMPACT platform. Our combination of exceptional talent, inclusive integration, and strong resolve will enable us to reach untapped biology of the adaptive immune system and make a major impact on treating autoimmune diseases.
Jo is a seasoned biotech executive and entrepreneurial scientist who has taken more than a dozen drugs to clinic over her 30-year career.
Prior to founding Seismic, she founded Pandion Therapeutics in 2017 and served as President and Chief Scientific Officer until the acquisition by Merck for $1.85B in 2021. Prior to Pandion, she held research leadership positions at Biogen, Amgen and Immunex. She is an experienced director on both private and public company boards.
In 2024 she was recognized as a Distinguished Fellow by the American Association for Immunologists. In 2022 she was named as one of the Extraordinary Women Advancing Healthcare in Massachusetts by The Women’s Edge, and she was profiled in the Boston Business Journal’s Women to Watch. Jo has also featured in FiercePharma’s 2020 Fiercest Women in Life Sciences and in Endpoints’ 2019 Special Report on 20 Extraordinary Women.
Jo is an advocate for workplace inclusiveness and regularly volunteers her time with organizations focused on increasing diversity. She has served on the board of WEST, a non-profit organization supporting early to mid-career women, including as President 2017-18.
Jo has a PhD in immunology from the University of London, and a BSc (Hons) in biophysics from the University of East London.
John is a rheumatologist and immunologist with over 25 years of experience in academic medicine and the biotechnology industry. His research career has focused on developing novel therapies for patients with inflammatory and fibrotic diseases.
He is an Independent Director of Sanofi S.A., a director of Neutrolis, Inc, and serves on the board of CARRA, the Childhood Arthritis and Rheumatology Research Alliance, and the Steering Committee of the NIH Immune Tolerance Network.
Prior to joining Seismic John was the Chief Medical Officer of Pandion Therapeutics, which was acquired by Merck in 2021 for $1.85 billion. He previously was Senior Vice President and Inflammation Therapeutic Area Head at Gilead Sciences. John led Gilead’s entry into inflammation and immunology and oversaw the clinical development of over a dozen new drug programs including Jyselica, which is approved in Europe and Japan for rheumatoid arthritis and/or ulcerative colitis.
Before moving to industry, John was a tenured Associate Professor of Medicine at Duke University and Associate Professor at the Duke-National University of Singapore Graduate Medical School. While at Duke he was instrumental in the Phase 1-3 development of Krystexxa which is approved for patients with refractory gout. In addition, he served as Associate Director of the Duke Clinical Research Institute and Director of Duke’s Global Proof of Concept Research Unit Network in the US, Singapore and India.
An undergraduate from Bucknell University, John received his medical and scientific education at Drexel University, and residency and fellowship training at Duke. He is a fellow of the American College of Rheumatology, the American Academy of Allergy Asthma and Immunology, and the American College of Physicians. John is an Adjunct Professor of Medicine at Duke University and has clinical privileges in rheumatology at the Duke-affiliated Durham VA Medical Center. He has authored over 100 scientific publications.
Maude is a deal maker and company builder with over 17 years of business development corporate strategy, and cross functional business experience in public and private biotechnology, pharmaceutical and academic organizations.
Prior to Seismic, she served as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions. She led key initiatives, including the negotiation of a $1B+ strategic partnership with BMS, the strategy and execution of the company rebranding and pipeline expansion into targeted oncology, the acquisition of Amplify Medicines, and drove core financing activities resulting in over $260M in private and public capital.
Previously, Maude was Executive Director, Business Development and Licensing at Merck & Co, leading oncology and immunology partnering in the Boston innovation hub. She served as Assistant Director, Business Development and Strategic Initiatives at Boston Children’s Hospital. She began her career at Xanthus Pharmaceuticals, where she had key roles in business development and program management of a Phase 3 drug candidate leading to its eventual FDA approval.
Maude is a co-chair of the Boston Biobreak CBO forum. She is an investment advisory board member for the Brown University Biomedical Innovations to Impact Fund, and a mentor for Endless Frontier Labs.
She holds an Honors Great Distinction BSc in Biochemistry from McGill University and a PhD from the Department of Medical Biophysics at the University of Toronto.
Kevin has more than 25 years of industry and academia experience in immunology. His work has largely focused on understanding lymphocyte activation and discovering and developing therapeutics to modulate lymphocyte activity.
Prior to Seismic, Kevin helped start Pandion Therapeutics as the second employee, where he led the Immunology and Biomarker groups. Kevin built a successful interdisciplinary discovery team at Pandion, which was acquired by Merck in 2021 for $1.85 billion, to discover and develop a pipeline of biologics-based therapies to treat autoimmunity.
Prior to Pandion, Kevin was a key member of the Immunology Pharmacology group at Abbvie where, among other responsibilities, he led the biology efforts to discover a small molecule GPCR agonist with colon-restricted activity to treat IBD. Before Abbvie, Kevin led the biology efforts at Biogen to discover and develop small molecule inhibitors of BTK to treat multiple autoimmune diseases and a biologics program targeting long-lived plasma cells.
Kevin is a member of the scientific advisory board of Eurofins Scientific.
Kevin graduated magna cum laude from Washington University in St. Louis with a bachelor’s degree in Molecular Biology and Biochemistry. He holds a Ph.D. in Immunology from the University of Washington in Seattle. Kevin did his post-doctoral training in Klaus Rajewsky’s lab at Harvard University.
Nathan has been creating innovative biologics drugs and drug technologies for over 15 years in both academia and industry.
Prior to joining Seismic, he served as VP of Biotherapeutics at Pandion Therapeutics where he played a pivotal role in growing Pandion from its earliest days in 2017 through several successful large financing rounds, an upsized IPO and the companies ultimate acquisition by Merck in 2021 for $1.85bn. Under Nathan’s leadership, Pandion’s Biotherapeutics group developed the tissue targeting TALON platform and created PT101, a now clinical stage TReg agonist.
Prior to Pandion, Nathan held various positions at Pfizer where he co-invented a proprietary bispecific platform, led an antibody optimization group, and led numerous technology development, drug discovery and preclinical stage projects across a number of therapeutic areas including inflammation and immunology. Nathan also worked at Google[x] to help launch Verily Life Sciences where he played a key role in the development of antibody-based capabilities designed to support a diagnostic nanoparticle platform.
Nathan believes that organizations can only truly succeed when people feel safe in bringing all of who they are to work. He co-founded the MA chapter of a Pfizer Colleague Resource Group for LGBTQ+ employees and allies. And drove Pandion’s participation in Boston Pride. Most recently Nathan volunteers time every week as a suicide and crisis intervention counsellor for The Trevor Project supporting LGBTQ+ youth in crisis.
Nathan began his career in antibody technology and molecular immunology at Imperial College London on a prestigious Wellcome Trust grant, where Nathan’s Ph.D focused on innovative methods for developing bi-paratopic antibodies using phage display.
Melanie is an experienced and versatile human resources leader with more than 18 years of experience supporting business plans and developing programs to fully engage talent in multiple industries, including at biopharmaceutical companies Novartis and Biogen.
Before joining Seismic, Manning held leadership positions at Enspira HR Consulting, where she served as Vice President, Human Capital, acting as primary contact for HR advisory client engagements. Prior to Enspira, she was Chief Human Resources Officer for non-profit organization Upstream USA. Previously, she served as Head of Human Resources for the Infectious Diseases division of Novartis Institutes for BioMedical Research (NIBR). Before her tenure at Novartis, Manning served as Associate Director, Human Resources at Biogen. Earlier in her career, she held several human resources positions for divisions of Fidelity Investments, which included HR business partner and Center of Excellence program office roles.
She has a Masters degree in Human Relations and a BA from the University of Oklahoma and completed Intensive Studies in French Literature and Civilization at Université de Clermont-Ferrand, France.
Brendan has more than 16 years of combined law firm and in-house experience in public and private biosciences companies.
Prior to joining Seismic, Brendan was General Counsel and Corporate Secretary for Synlogic, Inc., a publicly-traded biotech company with a phase 3 clinical drug program. Previously, he was Vice President, Legal, and member of the leadership team at Ohana Biosciences and was senior counsel at Vertex Pharmaceuticals. Brendan was a partner at the law firm of Donnelly, Conroy & Gelhaar, LLP, in Boston where he focused on complex commercial controversies and government enforcement. Earlier in his legal career, Brendan served as a clerk for the Hon. Alvin W. Thompson, Chief, U.S. District Court for the District of Connecticut and was an associate at the law firm of Goodwin Procter.
Brendan is co-chair of the MassBio General Counsel Roundtable and has served on several practice-related bar committees and on the executive committee of the Board of Trustees of the Massachusetts Continuing Legal Education corporation. He received his BA from Cornell University, JD from Harvard Law School, and his MPP from the Harvard Kennedy School.
Ed has more than 25 years of leadership experience directing finance, legal and operations activities in companies across multiple industries.
Prior to Seismic, Ed served as COO of Pandion Therapeutics as well as in CFO roles at Dyno Therapeutics, Faze Medicines, Kymera Therapeutics, Mana Therapeutics, KSQ Therapeutics, XTuit Pharmaceuticals, Oasys Water and Ensemble Therapeutics. Ed also served as General Counsel of Flagship Ventures (now Flagship Pioneering) and started his legal career at Testa, Hurwitz & Thibeault, LLP. Before going to law school, Ed was an accountant at Arthur Andersen & Co.
Ed earned his JD from Boston College Law School and his BSBA in Accounting from Boston University.
David brings over a decade of valuable experience in finance roles within the pharmaceutical and biotech sectors to Seismic Therapeutic.
Prior to joining Seismic, David held the position of Vice President of Finance at Sensei Biotherapeutics, where he led the Finance, Accounting, and Operations teams. He played a pivotal role in managing the finance and accounting functions, leading annual budgeting, cash planning, long-range planning, and external reporting. David also assisted the company’s transition to a public company, building out the Finance team, systems, and processes. Before his time at Sensei Biotherapeutics, David held various finance roles of increasing responsibility at Alexion Pharmaceuticals and Vertex Pharmaceuticals.
David holds a Bachelor of Business Administration in Finance from the University of Rhode Island.
Heather Vital joins Seismic with more than 15 years of experience across strategic and operational functions, including program and alliance management, portfolio planning and R&D strategy and commercialization.
Prior to Seismic, she was Senior Director, Portfolio Strategy and Operations for Relay Therapeutics, where she contributed to portfolio strategies for pipeline programs and was responsible for alliance management with a large biopharma partnership and a research collaboration. She served as Senior Director of Program Leadership at Deciphera Pharmaceuticals, where she was the program lead for two oncology drug programs including one through product approval. Previously, Heather had a tenure at Biogen, culminating in the role of Director, R&D Strategy and Portfolio Leadership and for several disease areas. Her earlier roles at Biogen included portfolio strategy for spinal muscular atrophy, launching SPINRAZA as part of the global brand team and new product commercialization for the immunology therapeutic area.
Heather has a BS from Babson College, MBA from the MIT Sloan School of Management, and a Master of Science (SM) from the Harvard-MIT Health Sciences and Technology Program.
Alan joined Polaris Partners in 2002 and serves as an entrepreneur partner. In this role, he focuses on building and investing in healthcare companies.
He has served as founder, chairman and/or CEO in building ten Polaris companies. Prior to founding Seismic, Alan co-founded Dyno Therapeutics along with Harvard Professor George Church and scientist Eric Kelsic. Dyno is using insights from computer science and biology to design better viruses for delivery of gene therapies. Prior to Dyno, Alan founded Pandion Therapeutics to focus on tissue-specific immunomodulation for autoimmune disorders and transplantation. In four years from the Polaris seed funding, Pandion became a clinical-stage, public company and was acquired by Merck for $1.85B. Alan’s past portfolio companies have collectively been involved in 12 IPOs and M&A exits.
His current and past portfolio includes: Momenta Pharmaceuticals (acquired by J&J), Pandion Therapeutics (acquired by Merck), Visterra (acquired by Otsuka), Dyno Therapeutics, KSQ Therapeutics, Sirtris Pharmaceuticals (acquired by GSK), Adnexus Therapeutics (acquired by BMS), Ocular Therapeutix, T2 Biosystems, Arsia Therapeutics (acquired by Eagle Pharmaceuticals), and Navitor Pharmaceuticals. From 2002 to 2006, Alan was president and CEO of Momenta Pharmaceuticals. He joined Momenta as the fifth employee and built it into a public company, creating an advanced and diversified pipeline. Momenta was acquired by J&J for $6.5B.
Prior to Polaris, Alan was senior vice president of global corporate development at Millennium Pharmaceuticals, where he was responsible for leading Millennium’s strategic partnering, mergers and acquisitions, and licensing activities, generating over $2B in partner funding to help fuel the company’s growth and acquiring 19 development stage products. Among these products was Velcade®, which became the main basis of the company’s $9B acquisition by Takeda.
Alan received Ernst & Young’s Entrepreneur of the Year award for New England while serving as CEO of Momenta. His current and former non-profit positions include: selection committee for the Harvard Life Lab, expert-in-residence at the Harvard School of Engineering, board member of the Boston Children’s Hospital Trust, founder of the Autism Consortium, and president of the board of Gann Academy.
Alan earned a BA in biology, summa cum laude, from Harvard College, an MA in biology from Harvard Graduate School of Arts & Sciences and an MBA from Harvard Business School. He also spent two years studying towards an MD at Harvard Medical School.
Shelley Chu has two decades of venture investing and operating experience in the biopharmaceutical industry. Her passion is working closely with entrepreneurs to navigate scientific, clinical, regulatory, business development and commercial hurdles to bring innovative new medicines to market that address significant unmet medical needs. To date, her investments across all stages, from seed to growth, have led to seven New Drug Approvals by the FDA, nine drug candidates in ongoing clinical development, and 16 exits through mergers and acquisitions, IPOs or partnerships. During her time at Gilead, where Shelley led R&D strategy across all therapeutic areas and business development in immuno-oncology and HBV, three NDAs were approved and launched.
At Lightspeed, Shelley leads the firm’s biotech investments from seed to late stage. In addition to Seismic, she is on the board of directors at Enlaza Therapeutics, 3T Biosciences, Medikine, Hillevax, Triana Biomedicines, Protego Biopharma, as well as an independent director for Scorpion Therapeutics. Shelley previously served on the Boards of Tizona Therapeutics (acquired by Gilead), Trishula Therapeutics (partnered with Abbvie), SFJ Pharmaceuticals, Phathom (Nasdaq: PHAT), Q32 Bio, IFM (acquired by BMS), IFM Tre (acquired by Novartis), IFM Due, IFM Quattro, and Venatorx. Shelley also invested in and worked closely with the management teams of Stromedix (acquired by Biogen), Rempex (acquired by The Medicines Company), Tobira (acquired by Allergan), Anaptys, Marcadia (acquired by Roche), Calixa (acquired by Cubist) and Cerexa (acquired by Forest). Shelley serves on the scientific advisory board for BioCentury.
Shelley holds an M.D. and a Ph.D. in biochemistry and biophysics from the University of California at San Francisco (UCSF) and a B.A. in molecular biology from Princeton University, where she is a co-chair for Princeton ASC.
Julie Eastland is Chief Executive Officer, President and Director of Zentalis Pharmaceuticals.
Previously Julie served as Chief Executive Officer and Board Director of Harpoon Therapeutics, formerly a publicly traded company (Nasdaq: HARP) focused on T-cell engager cancer immunotherapies, from November 2021 through its acquisition by Merck & Co in March of 2024. Prior to November 2021, she was a Harpoon Board Director and Chair of the Audit Committee from October 2018. She has served in a variety of C-level executive roles for both private and public companies, including Chief Operating Officer/Chief Financial Officer for ReCode Therapeutics, a private company developing genetic medicines; Chief Financial Officer/Chief Business Officer for Rainier Therapeutics, a private company focused on FGFR3 in bladder cancer; Chief Financial Officer/Chief Business Officer for Cascadian Therapeutics, a public company (CASC) focused on Tukysa (tucantinib) in HER2+ breast cancer, through its acquisition by Seagen in 2018. Prior to Cascadian, Julie served in a number of financial and strategic roles for VLST Corporation, focused on autoimmune and inflammation biology, Dendreon, an oncology cell therapy company marketing Provenge for prostate cancer, and Amgen.
Julie currently serves as a Board member and audit chair at Dynavax Technologies (DVAX), board and audit committee member at Lantheus Holdings Inc (LNTH) and board member at Veana Therapeutics (private). Previously, she was a Board Director and Chair of the Audit Committee for Graybug Vision and Harpoon Therapeutics. She received an M.B.A. from Edinburgh University Management School and a B.S. in finance from Colorado State University.
Andrew Hedin is a partner in Bessemer’s Cambridge office where he focuses on investments broadly across the healthcare ecosystem, including new biotech therapeutics as well as software and services sold to healthcare verticals.
Prior to joining Bessemer in 2015, Andrew worked at F-Prime Capital, Fidelity’s healthcare-focused venture capital fund where he invested in early-stage biotech and digital health technologies, as well as Leerink Partners as an advisor to the biopharma industry.
He earned an MBA with honors from The Wharton School, where he majored in health care management and finance, as well as a degree in biological basis of behavior from the University of Pennsylvania.
Timothy A. Springer, Ph.D. is the Latham Family Professor at the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Senior Investigator at the Program of Cellular and Molecular Medicine at Boston Children’s Hospital. He is a world leader in structural biology and immunology. He discovered many of the adhesion receptors in the immune system with monoclonal antibodies, then cloned and functionally and structurally characterized, them. He was the first to demonstrate that lymphocytes and leukocytes had adhesion molecules. His work on these receptors has advanced to characterizing their interactions and allosteric transitions by x-ray crystallography, electron microscopy, and laser tweezers force spectroscopy. In recognition of this work, he received the Canada Gairdner International Award in 2019, and was recently awarded the Biophysical Society’s Founder’s Award in 2021. He is a founder and private investor in biopharmaceutical ventures, including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases. Notably, he also co-founded the Institute for Protein Innovation: a non-profit to advance entrepreneurship and innovation in protein therapeutics and open-source antibodies and small molecules.
Jo is a seasoned biotech executive and entrepreneurial scientist who has taken more than a dozen drugs to clinic over her 30-year career.
Prior to founding Seismic, she founded Pandion Therapeutics in 2017 and served as President and Chief Scientific Officer until the acquisition by Merck for $1.85B in 2021. Prior to Pandion, she held research leadership positions at Biogen, Amgen and Immunex. She is an experienced director on both private and public company boards.
In 2024 she was recognized as a Distinguished Fellow by the American Association for Immunologists. In 2022 she was named as one of the Extraordinary Women Advancing Healthcare in Massachusetts by The Women’s Edge, and she was profiled in the Boston Business Journal’s Women to Watch. Jo has also featured in FiercePharma’s 2020 Fiercest Women in Life Sciences and in Endpoints’ 2019 Special Report on 20 Extraordinary Women.
Jo is an advocate for workplace inclusiveness and regularly volunteers her time with organizations focused on increasing diversity. She has served on the board of WEST, a non-profit organization supporting early to mid-career women, including as President 2017-18.
Jo has a PhD in immunology from the University of London, and a BSc (Hons) in biophysics from the University of East London.
Timothy A. Springer, Ph.D. is the Latham Family Professor at the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Senior Investigator at the Program of Cellular and Molecular Medicine at Boston Children’s Hospital. He is a world leader in structural biology and immunology. He discovered many of the adhesion receptors in the immune system with monoclonal antibodies, then cloned and functionally and structurally characterized, them. He was the first to demonstrate that lymphocytes and leukocytes had adhesion molecules. His work on these receptors has advanced to characterizing their interactions and allosteric transitions by x-ray crystallography, electron microscopy, and laser tweezers force spectroscopy. In recognition of this work, he received the Canada Gairdner International Award in 2019, and was recently awarded the Biophysical Society’s Founder’s Award in 2021. He is a founder and private investor in biopharmaceutical ventures, including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases. Notably, he also co-founded the Institute for Protein Innovation: a non-profit to advance entrepreneurship and innovation in protein therapeutics and open-source antibodies and small molecules.
Debora Marks, Ph.D. is an Associate Professor in the Department of Systems Biology at Harvard Medical School. As a mathematician and computational biologist, Marks develops novel algorithms, statistical methods and machine learning to successfully address unsolved biological problems. Her passion is to understand, predict and design biomolecular systems in a way that impacts biomedical applications and synthetic biology at many scales, with a focus on developing new methods in probabilistic modeling that exploit the huge and increasing corpus of natural and synthetic sequence diversity. Over the past five years, her lab has developed methods that accelerate structural biology with applications to cryoEM, crystallography, protein design and computed 3D structures of thousands of proteins with unknown folds, protein complexes and RNA interactions, as well as flexible, dynamic and even disordered protein ensembles. To address new challenges in protein design, Marks has adapted and developed NLP-inspired deep neural methods for (i) designing libraries of high affinity, specific nanobodies, antibodies that bypass the need for expensive rounds of selection or labor-intensive specificity assays and (ii) design and prediction of proteins that induce membranes compartmentalization and potentially biostasis in human cells and (iii) predicting the effect of genetic variation on disease and drug response. In 2016, Marks received the ICSB Overton Award for outstanding accomplishment in the early-to-mid career with significant contribution to the field of computational biology, and in 2018 the Chan Zuckerberg Initiative Ben Barres Early Career Acceleration Award in the Neurodegeneration Challenge.
Jeffrey V. Ravetch, M.D., Ph.D. is the Theresa and Eugene Lang Professor at the Rockefeller University and Head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology. His research has focused on synthetic oligoribonucleotides, the genetics of viral replication and gene expression for the single stranded DNA bacteriophage f1, and gene characterization for human antibodies and DNA elements involved in switch recombination. From 1982 to 1996 Dr. Ravetch was a member of the faculty of Memorial Sloan-Kettering Cancer Center and Cornell Medical College. His laboratory has focused on the Fc domain of antibodies and the receptors it engages, determining the mechanisms by which this domain enables antibodies to mediate their diverse biological activities in vivo. His work established the novel structural basis for Fc domain functional diversity and the pre-eminence of FcR pathways in host defense, inflammation and tolerance, describing novel inhibitory signaling pathways to account for the paradoxical roles of antibodies as promoting and suppressing inflammation. His work has been widely extended into clinical applications for the treatment of neoplastic, inflammatory and infectious diseases. Dr. Ravetch has received numerous awards including the Burroughs-Wellcome Scholar Award, the Pew Scholar Award, the Boyer Award, the NIH Merit Award, the Lee C. Howley, Sr. Prize (2004), the AAI-Huang Foundation Meritorious Career Award (2005), the William B. Coley Award (2007), the Sanofi-Pasteur Award (2012), the Gairdner International Prize (2012), the Wolf Prize in Medicine (2015), the Ross Prize in Molecular Medicine (2017) and the Robert Koch award (2018). He has also presented numerous named lectures. Ravetch has contributed extensively to the scientific community by serving as a member of the Scientific Advisory Boards of the Cancer Research Institute, the Irvington Institute for Medical Research, the Damon Runyon Foundation, the medical advisory board of Gairdner Foundation, the Sanofi-Pasteur Award Jury and the L’Oreal Women in Science Jury. He has been active in biotechnology for the last two decades, and currently serves as a consultant or member of the Scientific Advisory Boards of Asylia, Biohaven, Harpoon, IgGenix, Jasper, Palleon, Vir and Xencor.
Eric J. Sundberg, Ph.D. is Professor and Chair of Biochemistry at the Emory University School of Medicine in Atlanta, Georgia. His research has focused on emulsion polymerization, structure and function of bacterial superantigens, and the interactions of bacterial superantigens with T cell receptors and major histocompatibility complexes. In 2002, he was promoted to non-tenure track assistant professor at the Center for Advanced Research in Biotechnology, an institute of the University of Maryland, and was awarded his first NIH grant, which he leveraged to obtain an independent faculty position at the Boston Biomedical Research Institute (BBRI), in Watertown, Massachusetts. At BBRI, he broadened his research program to include studies of additional immune receptors and antibodies. In 2011, he returned to Maryland, this time to the Institute of Human Virology (IHV) and the Departments of Medicine and of Microbiology and Immunology at the University of Maryland School of Medicine. At IHV, his lab was next door to that of Lai-Xi Wang; together they began a collaboration on the structure and function of EndoS, the IgG-specific endoglycosidase, that continues to this day. He moved again in 2019 to become Chair of the Department of Biochemistry at the Emory University School of Medicine, where he continues to broaden his research program in glycobiology and infectious diseases. Dr. Sundberg has received numerous awards throughout his career, including an Arthritis Foundation Postdoctoral Fellowship, an Elsa U. Pardee Foundation Cancer Research Award, a Simeon J. Fortin Charitable Foundation Cancer Research Award, an Experienced Research Fellowship from the Alexander von Humboldt Foundation, an American Asthma Foundation Scholar Award, and a National Psoriasis Foundation Discovery Award. He serves the scientific community in myriad ways, most notably as Chair of the Public Affairs Committee of the Biophysical Society.
Andrew Kruse, Ph.D. is a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His research focuses on the structure and function of transmembrane receptors, with an emphasis on poorly understood transmembrane proteins. He began his independent career as an Assistant Professor at Harvard Medical School in 2014. Key research accomplishments include defining the structural basis for agonist action at the angiotensin II type 1 receptor and other G protein-protein coupled receptors (GPCRs), cloning the sigma-2 receptor, and determining the first structure of a tetraspanin protein and showing how it regulates B cell activation. The Kruse lab also developed a single-domain antibody fragment discovery platform that has now been distributed to more than 400 academic labs and has been licensed to four pharmaceutical companies. Dr. Kruse is a co-founder of Tectonic Therapeutic, a biotechnology company, and the Institute for Protein Innovation, a non-profit research organization. He has received awards including an Amgen Young Investigator Award (2019), an Alfred P. Sloan Research Fellowship (2017), a Vallee Scholars Award (2016), and an NIH Director’s Early Independence Award (2015). He received B.S. degrees in Mathematics and Biochemistry from the University of Minnesota in 2009, and completed a Ph.D. in Structural Biology at Stanford University in 2014, where he trained with Dr. Brian Kobilka.
This links to an external website.